IPP Bureau
CerroZone reduces airborne Covid-19 Delta variant by 99.998% in 1.2 seconds
By IPP Bureau - March 31, 2022
Air purification system achieves Intertek zero ozone certification
Symbiance announces the launch of SimpleStats to help pharma and biotech industries
By IPP Bureau - March 31, 2022
It is an application to automate statistical analysis and reporting for clinical research.
Researchers discover new model for "Global" DNA repair
By IPP Bureau - March 31, 2022
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Seventh international meet on Pharma and MedTech from April 25-27 in New Delhi
By IPP Bureau - March 31, 2022
The event will have a mix of policymakers, national and international leaders from the pharma industry, MSME, innovators, academic and research fraternity
Cipla Medpro South Africa partners with mAbxience for affordable cancer drugs
By IPP Bureau - March 31, 2022
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
National Health Authority releases consultation paper on Drug Registry
By IPP Bureau - March 31, 2022
The Drug Registry intends to create a nationally recognized source of information on various systems of medicine in the country
Phablecare acquires Fused Training, a startup combating Type-1 Diabetes
By IPP Bureau - March 31, 2022
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
USFDA approves Edwards Mitris Resilia valve
By IPP Bureau - March 31, 2022
The valve has a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve
SRV Hospitals and Lokmanya Hospital launch centre for robotic orthopaedics
By IPP Bureau - March 30, 2022
The SRV LHPL centre of excellence in robotic orthopaedics will be helmed by joint replacement surgeon, Dr Narendra Vaidya
Govt clears 49 applicants for PLI in Bulk Drugs
By IPP Bureau - March 30, 2022
The selected 49 applications are from 33 companies. Out of these 33 companies, 13 are Micro, Small and Medium Enterprises (MSMEs) besides some newly incorporated entities
Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors
By IPP Bureau - March 30, 2022
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Rotary Club of Delhi South carriers out large-scale relief work across leprosy colonies
By IPP Bureau - March 30, 2022
India accounts for more than half (almost 60%) of new leprosy cases worldwide, despite being declared ‘leprosy-free’ in 2005.
Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists
By IPP Bureau - March 30, 2022
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Medtronic commences PRAAN registry for stroke patients
By IPP Bureau - March 30, 2022
The registry will be conducted for approximately two and a half years and up to 200 subjects will be enrolled
OPPI summit calls for collaboration across stakeholders
By IPP Bureau - March 30, 2022
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
